Trial Profile
A Randomized, double-blind, placebo controlled multicentric Phase I/II study to evaluate the safety, tolerability and neutralizing activity of Rabimabs (A murine anti-rabies monoclonal antibody cocktails)against rabies virus in healthy subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Docaravimab/miromavimab (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 05 Dec 2016 Status changed from recruiting to completed.
- 25 Jan 2013 New trial record